MU
Micron Technology, Inc.
MU has the edge over PATH overall, supported by stronger valuation and stronger modeled upside.
PATH
UiPath Inc.
PATH's outlook is improving, though it still trails on the overall score.
MU Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
MU's revenue, profitability, cash flow and balance sheet are all currently strong.
PATH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
PATH's revenue, profitability, cash flow and balance sheet are all currently healthy.
MU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 4.6x | $798 | — |
| Cheap | 10x | $777 | -2.7% |
| Current | 11x | $798 | — |
| Fair | 22x | $1,646 | +106% |
| Expensive | 32x | $2,404 | +201% |
Historical ranges are pointers, not guarantees.
MU's PE is in its cheap range at 11x. If earnings grow as analysts expect, today's price would be 4.6x next year's earnings.
PATH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $13.10 | — |
| Cheap | 20x | $13.08 | -0.2% |
| Current | 20x | $13.10 | — |
| Fair | 23x | $15.26 | +16% |
| Expensive | 403x | $270 | +1960% |
Historical ranges are pointers, not guarantees.
PATH has the edge over MU in the historical PE scenario, which offers more potential upside but is not a forecast.
MU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for MU, with profitability improving.
PATH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for PATH, with profitability improving.
MU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $174.95 | +135% |
| Q3 2026 | $74.33 | +879% |
| Q2 2026 | $44.17 | +693% |
| Q1 2026 | $21.18 | +405% |
| Q4 2025 | $10.52 | +201% |
| Q3 2025 | $7.59 | +984% |
| Q2 2025 | $5.57 | +$6.99 |
| Q1 2025 | $4.19 | +$7.64 |
| Q4 2024 | $3.49 | +$9.77 |
MU's earnings per share have climbed steadily: $74.33 over the past year, about 10 times what it earned the year before, and higher year over year for 10 quarters in a row.
PATH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.88 | +31% |
| Q3 2026 | $0.67 | +2133% |
| Q2 2026 | $0.60 | +$0.72 |
| Q1 2026 | $0.52 | +$0.65 |
| Q4 2025 | $0.42 | +$0.57 |
| Q3 2025 | $0.03 | +$0.22 |
| Q2 2025 | -$0.12 | +$0.03 |
| Q1 2025 | -$0.13 | +$0.03 |
| Q4 2024 | -$0.15 | +$0.13 |
PATH's earnings per share have climbed steadily: $0.67 over the past year, more than ten times what it earned the year before, and higher year over year for 18 quarters in a row.
MU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.2B | +379% |
| Q2 2026 | $41.5B | +346% |
| Q1 2026 | $23.9B | +196% |
| Q4 2025 | $13.6B | +57% |
| Q3 2025 | $11.3B | +46% |
| Q2 2025 | $9.3B | +37% |
| Q1 2025 | $8.1B | +38% |
| Q4 2024 | $8.7B | +84% |
MU has the edge over PATH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 81% | +48 points |
| Q2 2026 | 80% | +57 points |
| Q1 2026 | 68% | +46 points |
| Q4 2025 | 45% | +20 points |
| Q3 2025 | 32% | +13 points |
| Q2 2025 | 23% | +13 points |
| Q1 2025 | 22% | +19 points |
| Q4 2024 | 25% | +49 points |
MU has the edge over PATH on profitability, with a higher operating margin.
PATH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $410.3M | +13% |
| Q2 2026 | $418.4M | +17% |
| Q1 2026 | $481.1M | +14% |
| Q4 2025 | $411.1M | +16% |
| Q3 2025 | $361.7M | +14% |
| Q2 2025 | $356.6M | +6.4% |
| Q1 2025 | $423.6M | +4.5% |
| Q4 2024 | $354.7M | +8.8% |
PATH's revenue has grown year over year every quarter since early 2021: $410M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.7% | +13 points |
| Q2 2026 | 6.7% | +11 points |
| Q1 2026 | 17% | +8.8 points |
| Q4 2025 | 3.2% | +15 points |
| Q3 2025 | -5.6% | +27 points |
| Q2 2025 | -4.6% | +10 points |
| Q1 2025 | 7.9% | +4.2 points |
| Q4 2024 | -12% | +4.9 points |
PATH's operating margin was 7.7% last quarter, up 13 points from the same quarter a year ago.
MU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.9B | +45543% |
| Q2 2026 | $17.6B | +951% |
| Q1 2026 | $5.5B | +$5.6B |
| Q4 2025 | $3B | +7853% |
| Q3 2025 | $72M | -75% |
| Q2 2025 | $1.7B | +322% |
| Q1 2025 | -$113M | +$52M |
| Q4 2024 | $38M | +$433M |
MU has the edge over PATH on cash flow, with more consistent year-over-year improvement.
PATH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $29.3M | -30% |
| Q2 2026 | $129.2M | +22% |
| Q1 2026 | $179.3M | +29% |
| Q4 2025 | $25.1M | +8.2% |
| Q3 2025 | $41.6M | -7.5% |
| Q2 2025 | $106.2M | +7.5% |
| Q1 2025 | $138.7M | -2.2% |
| Q4 2024 | $23.2M | -44% |
PATH generated $363M in free cash flow over the past year, up 17% from the year before.
MU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -2M shares |
| 1 year | +1.6% | +18M shares |
| 3 years | +4.6% | +50M shares |
| 5 years | +0.2% | +2M shares |
| Available history | +1.2% | +14M shares |
MU has 1.1B diluted shares, up 1.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $350M |
| Q4 2025 | $300M |
| Q3 2024 | $300M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
MU has spent almost nothing on buybacks in the past year.
PATH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -4.8M shares |
| 1 year | -3.7% | -19.9M shares |
| 3 years | -7.1% | -39.9M shares |
| 5 years | -0.7% | -3.5M shares |
| Available history | +6.3% | +30.9M shares |
PATH has the edge over MU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $24.8M |
| Q2 2026 | $243.8M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $101.6M |
| Q2 2025 | $227.5M |
| Q1 2025 | $9.3M |
| Q4 2024 | $162.7M |
PATH spent $269M buying back its own shares over the past year, down 46% from the year before.
MU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
MU has more cash than debt.
PATH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.4x | Net Cash |
| Q2 2026 | -5.2x | Net Cash |
| Q1 2026 | -11.8x | Net Cash |
| Q4 2025 | -29.4x | Net Cash |
PATH has the edge over MU on leverage, with a lower net debt burden relative to earnings.
MU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.1 | Neutral |
| Stochastic | 26.9 | Neutral |
MU's weekly RSI is 47 (neutral) and its Stochastic is 27 (neutral).
PATH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.6 | Neutral |
| Stochastic | 24.9 | Neutral |
PATH's weekly RSI is 50 (neutral) and its Stochastic is 25 (neutral).
MU PE vs Technology Sector
| Metric | MU | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 61% below |
| PE % | 18 | 35 | 17 pts below |
MU has the edge over PATH on valuation relative to its sector.
PATH PE vs Technology Sector
| Metric | PATH | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 30% below |
| PE % | 20 | 42 | 22 pts below |
PATH is trading at 20x earnings, a 30% discount to the Technology sector's median of 28x.
MU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $914.5 | 13% below |
| 20 week MA | $931.0 | 14% below |
| 50 week MA | $685.9 | 16% above |
| 100 week MA | $405.4 | 97% above |
| 200 week MA | $246.0 | 225% above |
MU has the edge over PATH on trend strength, trading above more of its moving averages.
PATH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.2 | 1% below |
| 20 week MA | $13.7 | 4% below |
| 50 week MA | $12.9 | 1.4% above |
| 100 week MA | $12.8 | 2.3% above |
| 200 week MA | $14.8 | 12% below |
PATH's trend is mixed: it's above two of its five weekly moving averages, and 12% below its 200-week average.
MU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.0 | $70.6 | +31% |
| 2021 | $70.6 | $94.4 | +34% |
| 2022 | $94.4 | $50.2 | -47% |
| 2023 | $50.2 | $85.3 | +70% |
| 2024 | $85.3 | $88.6 | +3.9% |
| 2025 | $88.6 | $284.8 | +221% |
| 2026 YTD | $284.8 | $798.4 | +180% |
MU has the edge over PATH on returns for 2026, with the stronger performance.
PATH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $74.8 | $44.4 | -41% |
| 2022 | $44.4 | $12.1 | -73% |
| 2023 | $12.1 | $24.8 | +105% |
| 2024 | $24.8 | $12.9 | -48% |
| 2025 | $12.9 | $16.8 | +31% |
| 2026 YTD | $16.8 | $13.1 | -22% |
PATH's yearly returns have swung widely, from +105% in 2023 to −73% in 2022. It's down 22% so far in 2026.